Gudrun Simons

Learn More
BACKGROUND Empagliflozin is a potent, selective sodium glucose cotransporter 2 (SGLT2) inhibitor in development as an oral antidiabetic treatment. This QT interval study assessed potential effects of empagliflozin on ventricular repolarisation and other electrocardiogram (ECG) parameters. METHODS A randomised, placebo-controlled, single-dose,(More)
  • 1